Meropenem + Vaborbactam for Injection bulk supplier for pharma manufacturers

Meropenem + Vaborbactam for Injection 1 g + 1 g Suppliers & Bulk Manufacturers

Available Forms: Powder for concentrate vial (IV infusion)

Available Strengths: 1 g + 1 g

Pack Sizes: Packs of 6 vials

Reference Brands: Vabomere (US), Vaborem (EU)

Meropenem-vaborbactam (Vabomere in the US, Vaborem in the EU) is a reserve antibiotic for infections caused by KPC-producing carbapenem-resistant Enterobacterales. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Meropenem + Vaborbactam for Injection? List it or send an offer →

Product Description:

Meropenem-vaborbactam pairs the carbapenem meropenem with vaborbactam, a boronic-acid beta-lactamase inhibitor. Vaborbactam is especially effective against the KPC carbapenemase, the enzyme behind many outbreaks of carbapenem-resistant Klebsiella pneumoniae. With vaborbactam present, meropenem regains its activity against these bacteria.

It is approved for complicated urinary tract infections including pyelonephritis, and in the EU also for complicated intra-abdominal infections, hospital-acquired pneumonia and other infections with limited options. Each 2 g dose (1 g meropenem plus 1 g vaborbactam) is infused over three hours every eight hours. It is not active against metallo-beta-lactamases (NDM, VIM) or OXA-48.

Sourcing notes. Meropenem-vaborbactam is patented and supplied by the originator companies. It sits in the WHO AWaRe Reserve group. Hospitals outside its registered markets can usually import it through named-patient routes. Plain meropenem injection is also listed on PharmaTradz.

How Meropenem + Vaborbactam for Injection is supplied today, and licensing ahead of patent expiry

Meropenem + Vaborbactam for Injection is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Meropenem + Vaborbactam for Injection, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Meropenem + Vaborbactam for Injection supply →

Back to Listing